Cole R Steber1, Ryan T Hughes1, James Urbanic2, Hollins Clark3, W Jeffrey Petty4, A William Blackstock1, Michael K Farris5. 1. Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina. 2. Department of Radiation Oncology, University of California, San Diego, California. 3. Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina. 4. Department of Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina. 5. Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina. Electronic address: mfarris@wakehealth.edu.
Abstract
PURPOSE: Long-term outcomes after external beam radiation therapy (EBRT) and radiofrequency ablation (RFA) for medically inoperable early-stage non-small cell lung cancer (NSCLC) are not well known. METHODS AND MATERIALS: Patients with medically inoperable early-stage NSCLC were enrolled in a prospective single-arm, phase 2 study between June 2007 and October 2008 and were treated with RFA followed by EBRT. Radiation was delivered using hypofractionated radiation therapy (HFRT; 70.2 Gy in 26 fractions) or stereotactic body radiation therapy (54 Gy in 3 fractions). RESULTS: Twelve patients were evaluable; 10 patients were treated with HFRT. The cumulative incidence of local progression at 5 years was 16.7% (95% confidence interval [CI], 0-37.8). Median progression-free survival was 37.8 months (95% CI, 11.1 to not reached) and median overall survival was 53.6 months (95% CI, 21.0 to not reached). There were no mortalities within 30 days after RFA and no grade ≥4 toxicity. CONCLUSIONS: The combination of RFA with EBRT appears feasible with favorable long-term local control. However, because SBRT alone has similar or better rates of control, we do not recommend routine combined RFA and EBRT.
PURPOSE: Long-term outcomes after external beam radiation therapy (EBRT) and radiofrequency ablation (RFA) for medically inoperable early-stage non-small cell lung cancer (NSCLC) are not well known. METHODS AND MATERIALS: Patients with medically inoperable early-stage NSCLC were enrolled in a prospective single-arm, phase 2 study between June 2007 and October 2008 and were treated with RFA followed by EBRT. Radiation was delivered using hypofractionated radiation therapy (HFRT; 70.2 Gy in 26 fractions) or stereotactic body radiation therapy (54 Gy in 3 fractions). RESULTS: Twelve patients were evaluable; 10 patients were treated with HFRT. The cumulative incidence of local progression at 5 years was 16.7% (95% confidence interval [CI], 0-37.8). Median progression-free survival was 37.8 months (95% CI, 11.1 to not reached) and median overall survival was 53.6 months (95% CI, 21.0 to not reached). There were no mortalities within 30 days after RFA and no grade ≥4 toxicity. CONCLUSIONS: The combination of RFA with EBRT appears feasible with favorable long-term local control. However, because SBRT alone has similar or better rates of control, we do not recommend routine combined RFA and EBRT.
Authors: Robert D Timmerman; Rebecca Paulus; Harvey I Pass; Elizabeth M Gore; Martin J Edelman; James Galvin; William L Straube; Lucien A Nedzi; Ronald C McGarry; Cliff G Robinson; Peter B Schiff; Garrick Chang; Billy W Loo; Jeffrey D Bradley; Hak Choy Journal: JAMA Oncol Date: 2018-09-01 Impact factor: 31.777
Authors: Andrea Bezjak; Rebecca Paulus; Laurie E Gaspar; Robert D Timmerman; William L Straube; William F Ryan; Yolanda I Garces; Anthony T Pu; Anurag K Singh; Gregory M Videtic; Ronald C McGarry; Puneeth Iyengar; Jason R Pantarotto; James J Urbanic; Alexander Y Sun; Megan E Daly; Inga S Grills; Paul Sperduto; Daniel P Normolle; Jeffrey D Bradley; Hak Choy Journal: J Clin Oncol Date: 2019-04-03 Impact factor: 44.544
Authors: C Alexander Grieco; Caroline J Simon; William W Mayo-Smith; Thomas A DiPetrillo; Neal E Ready; Damian E Dupuy Journal: J Vasc Interv Radiol Date: 2006-07 Impact factor: 3.464
Authors: Jeffrey D Bradley; Sasha Wahab; Mary Ann Lockett; Carlos A Perez; James A Purdy Journal: Int J Radiat Oncol Biol Phys Date: 2003-06-01 Impact factor: 7.038
Authors: Damian E Dupuy; Thomas DiPetrillo; Sachin Gandhi; Neal Ready; Thomas Ng; Walter Donat; William W Mayo-Smith Journal: Chest Date: 2006-03 Impact factor: 9.410
Authors: Jeffrey A Bogart; Lydia Hodgson; Stephen L Seagren; A William Blackstock; Xiaofei Wang; Robert Lenox; Andrew T Turrisi; John Reilly; Ajeet Gajra; Everett E Vokes; Mark R Green Journal: J Clin Oncol Date: 2009-11-23 Impact factor: 44.544
Authors: Gregory M M Videtic; Chen Hu; Anurag K Singh; Joe Y Chang; William Parker; Kenneth R Olivier; Steven E Schild; Ritsuko Komaki; James J Urbanic; Robert D Timmerman; Hak Choy Journal: Int J Radiat Oncol Biol Phys Date: 2015-07-17 Impact factor: 7.038
Authors: Patrick Cheung; Sergio Faria; Shahida Ahmed; Pierre Chabot; Jonathan Greenland; Elizabeth Kurien; Islam Mohamed; James R Wright; Helmut Hollenhorst; Catherine de Metz; Holly Campbell; Thi Toni Vu; Anand Karvat; Elaine S Wai; Yee C Ung; Glenwood Goss; Frances A Shepherd; Patti O'Brien; Keyue Ding; Chris O'Callaghan Journal: J Natl Cancer Inst Date: 2014-07-29 Impact factor: 13.506